Ozempic Gastrointestinal Injury Lawsuit

Ozempic, generically known as semaglutide, and is developed and manufactured by Novo Nordisk based in Denmark.

Ozempic Gastrointestinal Injury Lawsuit. Ozempic is a prescription injectable only medication, approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes in December, 2017.

Ozempic mechanism of action for the treatment of type 2 diabetes is via glucagon-like peptide-1 (GLP-1) receptor agonist action. These GLP-1 receptor agonist class of drugs lower blood sugar levels in the body by increasing insulin release by the pancreas, by reducing sugar production and releasing of sugar by the liver and slowing down food leaving the stomach, according to Novo Nordisk.

Researchers noted that in addition to treating type 2 diabetes, these medications had an interesting side effect in that they also caused weight loss.

Novo Nordisk in 2019 was approved by the FDA for an oral version of semaglutide in tablet form for the treatment of type 2 diabetes called Rybelsus.

Wegovy is approved by the FDA for Weight Loss

The FDA approved Wegovy (semaglutide) injection also made by Novo Nordisk for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol).

Wegovy is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014.

Ozempic and Rybelsus Off Label Use

Ozempic and Rybelsus medications were approved to treat patients with type 2 diabetes, but these drugs sales exploded in off-label use (which occurs when a drug is used to treat a medical condition other than its FDA-approved specific criteria) once it was discovered that these medications also caused patients mild to modest weight loss.

Novo Nordisk aggressive multi-million dollar Ozempic marketing emphasized the weight loss benefits, and also social media celebrity endorsers massively increased the popularity of Ozempic for weight loss purposes.

Ozempic, Wegovy and Rybelsus Side Effects

Shortly after hundreds of thousands patients used semaglutide for weight loss, many adverse reports surfaced about critical gastrointestinal side effects from Ozempic, Wegovy and Rybelius. These include severe nausea, vomiting and a medical condition called gastroparesis.

Patients suffering from gastroparesis may not have normal stomach content emptying leading vomiting of undigested food and malnutrition.

Did Novo Nordisk Failed to Disclose GI Side Effects?

According to some legal experts, it appears that Novo Nordisk knew or should have known about the risk of long-term Ozempic stomach problems, but failed to adequately disclose these increased side effects.

Ozempic Gastrointestinal Injury Lawsuit

Ozempic Gastrointestinal Injury Lawsuits are being investigated and filed for patients throughout the United States, noting that there is medical research evidence from that has established a link between Ozempic and gastrointestinal side effects that may be permanent despite the stoppage of this drug.

Ozempic Gastroparesis Side Effects

• Nausea
• Vomiting
• Early satiety, feeling full quickly after eating
• Abdominal pain

Ozempic Use Linked to Gallbladder Disease

A 2017 medical study found that Ozempic use increase risk of gallbladder disease including gall-stones and gallbladder inflammation.

Ozempic Vomiting Risks During Anesthesia Surgery

Recently, in July 2023, the American Society of Anesthesiologists (ASA) released a guidance focusing on the risk of gastroparesis during surgery, from the use of Ozempic and Wegovy.

Because of gastroparesis Ozempic patients may face an increased risk of suffocation and aspiration of food into the lungs during general anesthesia and deep sedation.

Dr. Shezad Malik Law Firm Investigating Ozempic Cases Nationwide

Did you or a loved one experience injuries after taking Ozempic, Wegovy, Rybelsus, or Mounjaro? Dr. Shezad Malik law firm based in Dallas, Texas is now reviewing injuries after taking Ozempic, Wegovy, Rybelsus, Mounjaro or other GLP-1 agonists cases nationwide. Please call 214-390-3189 or email us for further information.